The Global HIV Vaccine Enterprise is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by:
- Shared scientific plan: Implementing a strategic plan for HIV vaccine research that spans vaccine discovery, product development and manufacturing, and clinical trials
- Increased resources: Mobilizing significant new funding to achieve the scientific plan
- Greater collaboration: Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts
The Enterprise Approach »
|
 |
Canada's Government and the Bill & Melinda Gates Foundation have committed major new funding to support the Canadian HIV Vaccine Initiative, an effort to accelerate the development of an HIV vaccine and address critical research gaps identified by the Global HIV Vaccine Enterprise.
Press Release » Backgrounder »
The European and Developing Countries Clinical Trials Partnership (EDCTP) and the Bill & Melinda Gates Foundation launch a 20 M Euro call to develop HIV vaccine trial capacity in Africa. The call is being done in support of the Global HIV Vaccine Enterprise and the initial focus of the funding will be on the preparation of phase II clinical trials of HIV candidate vaccines, but where appropriate, the funds may also be used to conduct trials.
Press Release » Call for Proposals »
The Enterprise's scientific strategic plan for accelerating HIV vaccine research was published in the February 2005 issue of Public Library of Science (PLoS) Medicine.
Vaccine Discovery
The immediate goal is to design candidate vaccines that cause the immune system to produce protective responses from both of its major arms cellular immunity and neutralizing antibodies.
Read More »
|
Laboratory Standardization
The laboratory assays that researchers use to assess immune response may not be comparable, severely hampering decisions about which candidates to pursue for further testing.
Read More »
|
Product Development and Manufacturing
Once researchers have identified a vaccine design that they believe is promising, a critical phase of vaccine research is developing a manufacturing process that yields consistent batches over time.
Read More »
|
Clinical Trials Capacity
Three phases of clinical trials in humans are required to fully test a vaccine candidate.
Read More »
|
Regulatory Issues
National regulatory oversight of clinical trials is the cornerstone of safe and scientifically valid medical research.
Read More »
|
Intellectual Property Issues
Researchers routinely seek patents and other intellectual property protections for their inventions.
Read More »
|
|
